1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Innate Pharma S.A.

Innate Pharma S.A.

IPHYF
Innate Pharma S.A.US flagOther OTC
1.65
USD
- -
- -
154.94MMarket Cap
Innate Pharma S.A.
IPHYF
(Other OTC)

Recent

price

1.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.12
0.2
0.27
0.32
0.02
0.34
1.04
0.6
1.36
1.03
0.71
0.15
0.62
0.62
0.16
0.03
Revenue per Share
-0.36
-0.19
-0.08
-0.07
-0.39
-0.13
0.23
-0.89
0.05
-0.31
-0.81
-0.66
-0.73
-0.09
-0.61
-0.55
Basic EPS, GAAP
-0.37
0.34
-0.32
-0.29
-0.41
3.75
-0.86
-1
-0.58
-0.46
-0.8
-0.75
-0.25
-0.63
-0.09
-0.39
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.31
-2.17
-2.25
-2.27
-2.13
-2.13
-1.87
-2.74
-2.24
-2.27
-2.74
-3.37
-4.1
-3.96
-4.72
-4.81
Book Value per Share
0.9
0.71
0.62
1.04
1.38
1.17
1.43
0.73
1.41
1.8
1.39
0.8
0.66
0.61
0.11
-0.24
Tangible Book Value per Share
37
38
38
39
50
53
54
54
59
67
79
80
80
84
81
90
Basic Weighted Avg Shares
4
7
10
12
1
18
56
33
80
69
56
12
50
52
13
3
Sales/Revenue/Turnover
-316.9
-101.29
-32.47
-22.24
-2,201.43
-60.16
13.48
-122.53
6.44
2.29
1.92
-394.94
-33.13
-24.41
-408.65
-1,916.94
Operating Margin (%)
1
1
1
1
2
3
3
4
7
17
57
5
45
1
2
5
Depreciation Expense
-14
-7
-3
-3
-20
-7
13
-48
3
-21
-64
-53
-58
-8
-49
-49
Net Income, GAAP
- -
- -
- -
- -
- -
- -
2.33
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-316.16
-93.64
-30.83
-23.19
-2,166.15
-37.45
22.51
-148.28
3.82
-30.26
-113.94
-436.08
-117.19
-14.59
-391.97
-1,764.51
Profit Margin (%)
33
37
26
40
69
192
154
64
123
116
128
58
98
108
53
10
Working Capital
7
4
3
4
4
3
4
5
3
17
17
14
40
31
22
14
LT Debt
34
27
23
40
75
72
86
86
167
217
156
107
54
52
9
-22
Total Equity
- -
- -
- -
- -
- -
- -
8.44
- -
- -
0.75
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-12.43
- -
- -
15.81
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-39.79%
-102.71%
-345.69%
Free Cash Flow
33.58%
76.49%
379.07%
Net Income, GAAP
-99.17%
91.7%
-0.59%
Sales/Revenue/Turnover
36.64%
16.41%
-77.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
52
2024
- -
- -
- -
- -
13
2025
- -
- -
- -
- -
3

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.09
2024
- -
- -
- -
- -
-0.61
2025
- -
- -
- -
- -
-0.55

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
NurExone Biologic Inc. (NRXBF)
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378.HK)
Blue Jet Healthcare Limited (BLUEJET.BO)
BB Biotech AG (BION.SW)
Esperion Therapeutics, Inc. (ESPR)
YD Bio Limited Warrants (YDESW)
Business
Innate Pharma SA, a clinical-stage biotechnology company, develops immunotherapies that harness the innate immune system to treat cancer patients through antibody drug conjugates, monoclonal antibodies, and multi-specific NK cell engagers via its proprietary ANKET platform. Its lead pipeline candidates include IPH4502, a Nectin-4-targeted ADC for solid tumors; lacutamab, an anti-KIR3DL2 monoclonal antibody for advanced cutaneous T-cell lymphomas and peripheral T-cell lymphomas; and monalizumab, an anti-NKG2A antibody partnered with AstraZeneca for non-small cell lung cancer, with additional assets such as IPH5201 (anti-CD39, partnered with AstraZeneca), IPH5301 (anti-CD73), and the BCMA-targeted ANKET program with Sanofi for autoimmune indications. The company operates primarily in Europe and the United States, serving oncology patients with high unmet needs through collaborations with biopharmaceutical leaders including AstraZeneca, Sanofi, and research institutions. Founded in 1999 and headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, Innate Pharma lists on Euronext Paris and Nasdaq. Recent developments include a €15 million equity investment from Sanofi in April 2025 amid ongoing BCMA ANKET partnership; FDA clearance for the TELLOMAK-3 trial of lacutamab; prioritization of IPH4502, lacutamab, and monalizumab with approximately 30% staffing reductions for resource focus; enrollment completion in AstraZeneca's Phase 3 PACIFIC-9 monalizumab trial, with data expected in second-half 2026; and advancement of preclinical ADCs leveraging innovative targets.

Company News

APIChatGPT

  • businesswire.com

    Outcome of Innate Pharma's 2026 Annual General Meeting